Wolverine Asset Management’s Drugs Made In America Acquisition Corp Rights DMAAR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$41.9K Buy
693,136
+130,000
+23% +$13.8K ﹤0.01% 1278
2025
Q4
$105K Sell
563,136
-2
-0% ﹤0.01% 1178
2025
Q3
$122K Sell
563,138
-37,900
-6% -$7.05K ﹤0.01% 1081
2025
Q2
$72.2K Sell
601,038
-2,000
-0.3% -$257 ﹤0.01% 1172
2025
Q1
$78.4K Buy
+603,038
New +$84.7K ﹤0.01% 1123

Other funds holding DMAAR

Wolverine Asset Management's DMAAR Position: Q1 2026 in Review

Wolverine Asset Management increased its Drugs Made In America Acquisition Corp Rights (DMAAR) stake by 23% in Q1 2026, buying an estimated $13.8K and bringing the position to 693,136 shares worth $41.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1278.

Wolverine Asset Management first reported a position in DMAAR in Q1 2025 and has held it in 5 quarters since. The position peaked at $122K in Q3 2025. 35 funds tracked by Wall St. Rank hold DMAAR as of Q1 2026.

  • Wolverine Asset Management held 693,136 shares of Drugs Made In America Acquisition Corp Rights worth $41.9K as of Q1 2026.
  • Wolverine Asset Management bought 130,000 Drugs Made In America Acquisition Corp Rights shares in Q1 2026, an estimated $13.8K.
  • Drugs Made In America Acquisition Corp Rights made up ﹤0.01% of Wolverine Asset Management's portfolio in Q1 2026, its #1278 holding.
  • Wolverine Asset Management first reported a position in Drugs Made In America Acquisition Corp Rights in Q1 2025 and has held it in 5 quarters since.
  • Wolverine Asset Management's Drugs Made In America Acquisition Corp Rights position peaked at $122K in Q3 2025.
  • 35 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Rights as of Q1 2026.

Based on Wolverine Asset Management's 13F filing for Q1 2026, filed 4 May 2026.